Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
431-01-007 / 431-01-007 ISMRM Abstract

Application of fluid-suppressed APTw imaging in distinguishing glioma recurrence from post-treatment response

Primary: Contrast Mechanisms - CEST / APT / NOE
Secondary: Neuro - Tumors
431-01-007 · From Microstructure to Metabolism: Next-Generation MRI for Brain Tumors · Tuesday, 12 May, 8:20 AM–9:56 AM · Roof Terrace
431-01-007 · From Microstructure to Metabolism: Next-Generation MRI for Brain Tumors · Tuesday, 12 May, 8:20 AM–9:56 AM · Roof Terrace
Accepted
Jingwen Hou1, Chunqiu Su1, Gaoxue Lin1, Hongli Bian1, Yuandong Cao1, Xiance Zhao 2, Feiyun Wu1, Shanshan Lu1
1the first affiliated hospital of nanjing medical university, Nanjing, China
2Clinical and Technical Support, Philips Healthcare (Beijing), Beijing, China
Presenting Author: Xiance Zhao

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Zhou J, Payen JF, Wilson DA, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med. 2003;9(8):1085-1090. doi: 10.1038/nm907. [doi]
2. Essed RA, Prysiazhniuk Y, Wamelink IJ, et al. Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases. Eur Radiol. 2025;35(2):580-591. doi: 10.1007/s00330-024-11004-y. [doi]
3. Liu J, Li C, Chen Y, et al. Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T. J Magn Reson Imaging. 2020;51(4):1154-1161. doi: 10.1002/jmri.26900. [doi]
4. Zhou J, Zaiss M, Knutsson L, et al. Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: Application to brain tumors. Magn Reson Med .2022;88(2):546-574. doi: 10.1002/mrm.29241. [doi]
5. Keupp J, Togao O. Magnetization Transfer Ratio based Metric for APTw or CESTw MRI Suppressing Signal from Fluid Compartments-Initial Application to Glioblastoma Assessment. https://archive.ismrm.org/2018/3156.html. Published June 16,2018. Accessed February 28, 2023.
6. Mancini L, Casagranda S, Gautier G, et al. CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing. Eur J Nucl Med Mol Imaging. 2022;49(7): 2377-2391. doi: 10.1007/s00259-022-05676-1. [doi]
7. Nichelli L, Casagranda S, Dipasquale O, et al. Fluid-Suppressed Amide Proton Transfer-Weighted Imaging Outperforms Leakage-Corrected Dynamic Susceptibility Contrast Perfusion in Distinguishing Progression from Radionecrosis in Brain Metastases. Cancers (Basel). 2025;17(7):1175. doi: 10.3390/cancers17071175. [doi]
8. Ma B, Blakeley JO, Hong X, et al. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging. 2016;44(2):456-462. doi: 10.1002/jmri.25159. [doi]
9. Jiang S, Eberhart CG, Lim M, et al. Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy. Clin Cancer Res. 2019;25(2):552-561. doi: 10.1158/1078-0432.CCR-18-1233. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/431-01-007